4-(二甲基氨基)烟腈 | 435271-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(二甲基氨基)烟腈
• 英文名称: 4-(dimethylamino)nicotinonitrile
• 英文别名: 4-(dimethylamino)pyridine-3-carbonitrile
• CAS: 435271-24-2
• 化学式: C₈H₉N₃
• mdl: MFCD09263807
• 分子量: 147.18
• InChiKey: UFTOHTRIMQQBQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(二甲基氨基)烟腈 在 氨 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 反应 7.0h， 以467 mg的产率得到3-(aminomethyl)-N,N-dimethylpyridin-4-amine
  参考文献：
  名称：

  WO2020035052A5

  摘要：

  公开号：

  WO2020035052A5
• 作为产物：
  描述：

  4-甲苯磺酰氰 、 3-溴-4-N,N-二甲氨基吡啶 在 异丙基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以74%的产率得到4-(二甲基氨基)烟腈
  参考文献：
  名称：

  Efficient C-3 functionalization of 4-dimethylaminopyridine (DMAP). A straightforward access to new chiral nucleophilic catalysts

  摘要：

  Herein, the straightforward C-3 functionalization of 4-dimethylaminopyridine (DMAP) backbone is disclosed. An efficient halogen-metal exchange procedure from 3-bromo DMAP 1 is reported providing a large panel of C-3 functionalized DMAPs. In addition, a Pd-catalysed C-N cross-coupling reaction is also described furnishing new 3-amino DMAPs. These new functionalization pathways led to the resolution-free synthesis of three new chiral DMAP catalysts in few steps and a good overall yield. These new catalysts were evaluated into the Steglich rearrangement giving modest enantioselectivities (up to 20% ee). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.04.068

文献信息

• Pyrazine compounds and uses thereof
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US10898481B2

  公开（公告）日：2021-01-26

  The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

  本公开涉及以腺苷受体（特别是 A1 和 A2，尤其是 A2a）为靶点的新型吡嗪化合物。本公开还涉及包含一种或多种化合物作为活性成分的药物组合物，以及这些化合物在治疗腺苷受体（AR）相关疾病中的用途，例如癌症，如 NSCLC、RCC、前列腺癌和乳腺癌。
• PYRAZINE COMPOUNDS AND USES THEREOF
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US20200330458A1

  公开（公告）日：2020-10-22

  The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
• WO2020035052A5
  申请人：——

  公开号：WO2020035052A5

  公开（公告）日：2022-08-04
• Efficient C-3 functionalization of 4-dimethylaminopyridine (DMAP). A straightforward access to new chiral nucleophilic catalysts
  作者：Thomas Poisson、Sylvain Oudeyer、Vincent Levacher

  DOI：10.1016/j.tetlet.2012.04.068

  日期：2012.6

  Herein, the straightforward C-3 functionalization of 4-dimethylaminopyridine (DMAP) backbone is disclosed. An efficient halogen-metal exchange procedure from 3-bromo DMAP 1 is reported providing a large panel of C-3 functionalized DMAPs. In addition, a Pd-catalysed C-N cross-coupling reaction is also described furnishing new 3-amino DMAPs. These new functionalization pathways led to the resolution-free synthesis of three new chiral DMAP catalysts in few steps and a good overall yield. These new catalysts were evaluated into the Steglich rearrangement giving modest enantioselectivities (up to 20% ee). (C) 2012 Elsevier Ltd. All rights reserved.